Amolyt Pharma is currently testing a series of novel, small peptide antagonists of the growth hormone (GH) receptor to select a lead development candidate for treatment of acromegaly, under a research collaboration with Peptidream.

Acromegaly is a rare disease characterized by abnormally high levels of GH, which in turn causes excess production of insulin-like growth factor-1 (IGF-1). By preventing the interaction between GH and its receptor, the antagonist peptides are expected to normalize the excess IGF-1 in patients with acromegaly.

To date, there have been over 140 peptides designed from the originally discovered GH antagonist peptide, and that have been optimized to provide greater potency and efficacy.

AZP-38XX Acromegal
Scroll to Top